Kimialys Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
26
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$4.2M
- Investors
-
13
Kimialys General Information
Description
Developer of customized biofunctionalized nanoparticles and surfaces designed to improve the performance of in vitro diagnostics. The company provides coated gold nanoparticles, biochips, and contract development services to optimize assay performance and detection reliability, enabling assay developers, point of care test developers, and pharmaceutical laboratories to improve rapid test and in vitro analysis accuracy while lowering development and production costs.
Contact Information
Website
www.kimialys.comCorporate Office
- 2 Rue Dante
- 75005 Paris
- France
Corporate Office
- 2 Rue Dante
- 75005 Paris
- France
Kimialys Timeline
Kimialys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | 23-Dec-2025 | $4.2M | Completed | Generating Revenue | ||
| 6. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 5. Accelerator/Incubator | 01-Dec-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 26-Apr-2023 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Oct-2022 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 14-Dec-2020 | $214K | $214K | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 01-Jan-2020 | Completed | Startup |
Kimialys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| AP1DSA | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Kimialys Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kimialys Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kimialys Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angels Santé | Angel Group | Minority | ||
| Evolem | Family Office | Minority | ||
| Les Business Angels des Grandes Écoles | Angel Group | Minority | ||
| Octalfa | Venture Capital | Minority | ||
| Super Capital | Venture Capital | Minority |
Kimialys FAQs
-
When was Kimialys founded?
Kimialys was founded in 2020.
-
Where is Kimialys headquartered?
Kimialys is headquartered in Paris, France.
-
What is the size of Kimialys?
Kimialys has 26 total employees.
-
What industry is Kimialys in?
Kimialys’s primary industry is Biotechnology.
-
Is Kimialys a private or public company?
Kimialys is a Private company.
-
What is the current valuation of Kimialys?
The current valuation of Kimialys is .
-
What is Kimialys’s current revenue?
The current revenue for Kimialys is .
-
How much funding has Kimialys raised over time?
Kimialys has raised $5.43M.
-
Who are Kimialys’s investors?
Angels Santé, Evolem, Les Business Angels des Grandes Écoles, Octalfa, and Super Capital are 5 of 13 investors who have invested in Kimialys.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
